These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20943761)

  • 1. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
    Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
    Zeng X; Zhang H; Oh A; Zhang Y; Yee D
    Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
    Zhang Y; Wang Q; Chen L; Yang HS
    Mol Cancer Ther; 2015 Mar; 14(3):799-809. PubMed ID: 25573956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
    Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
    Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer.
    Leiphrakpam PD; Agarwal E; Mathiesen M; Haferbier KL; Brattain MG; Chowdhury S
    Oncol Rep; 2014 Jan; 31(1):87-94. PubMed ID: 24173770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
    Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
    Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
    McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
    Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
    Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
    Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.